ArticleSovremennye tekhnologii v meditsine2025
Development of DNA Microarray for Indication of Viral Community-Acquired Pneumonia Pathogens.
Article in Sovremennye tekhnologii v meditsine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Materials and Methods: The study materials were swab samples from the nasopharyngeal and oropharyngeal mucous membranes of patients aged 2 months to 18 years with X-ray confirmed pneumonia. The selection of DNA probes for the specific detection of viral community-acquired pneumonia pathogens and development of the microarray design were carried out using our previously developed disprose program. The nucleotide sequences of pathogens were obtained from the NCBI Nucleotide and GISAID databases. The selected DNA probes were synthesized on CustomArray slides (USA). The optimal hybridization temperature was selected on a model pooled sample containing adenovirus DNA and SARS-CoV-2 coronavirus RNA. The selection criteria were the percentage of effective probes with a standardized hybridization signal (SHS) ≥3 Z and the excess of SHS levels of effective specific probes compared to SHS of effective non-specific probes. The DNA probes were selected for the specific detection of viral community-acquired pneumonia pathogens, characterized by an effective hybridization signal under the identified conditions. Using ROC analysis, threshold values of specific probe signals were established, the excess of which was interpreted as the evidence of the pathogen presence in a sample. Results: A microarray design included 544 DNA probes for the detection of adenovirus, bocavirus, respiratory syncytial virus, metapneumovirus, parainfluenza virus, rhinovirus, and coronavirus. The DNA probes were synthesized on slides. The optimal DNA hybridization temperature on microarrays was established (47°C). A list of probes for specific detection of adenovirus group B, bocavirus, parainfluenza virus type 3, respiratory syncytial virus, rhinovirus, and SARS-CoV-2 coronavirus, characterized by an effective hybridization signal under the identified conditions, was selected. The threshold values of probe signals for specific detection of these pathogens in clinical samples were determined. Conclusion: A DNA microarray for the indication of viral community-acquired pneumonia pathogens was developed and synthesized. The interpretation of the hybridization results corresponds to the results obtained by the PCR method. The developed microarray can be used to improve laboratory diagnostics of viral community-acquired pneumonia pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.